Evidence map›Paper›PMID 27914267›Full record

ArticleBiomaterials2017

Intein-mediated site-specific synthesis of tumor-targeting protein delivery system: Turning PEG dilemma into prodrug-like feature.

Yingzhi Chen, Meng Zhang, Hongyue Jin, Yisi Tang, Huiyuan Wang, Qin Xu, Yaping Li, Feng Li, Yongzhuo Huang

Open access · greenAbstract read
In one paragraph

Article in Biomaterials, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 66 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Toxic proteins application in cancer therapy.Molecular biology reports · 2021
    Review
  13. Review
  14. Review
  15. Article
  16. Advances on Tumor-Targeting Delivery of Cytotoxic Proteins.ACS pharmacology & translational science · 2020
    Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Yingzhi ChenShanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Hai-ke Rd, Shanghai 201203, China; University of Chinese Academy of Sciences, 19A Yuquan Rd, Beijing 100049, China.
Meng ZhangShanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Hai-ke Rd, Shanghai 201203, China; University of Chinese Academy of Sciences, 19A Yuquan Rd, Beijing 100049, China.
Hongyue JinShanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Hai-ke Rd, Shanghai 201203, China.
Yisi TangGuangzhou University of Chinese Medicine Tropical Medical Institute, 12 Ji-chang Rd, Guangzhou 510405, China.
Huiyuan WangShanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Hai-ke Rd, Shanghai 201203, China.
Qin XuGuangzhou University of Chinese Medicine Tropical Medical Institute, 12 Ji-chang Rd, Guangzhou 510405, China.
Yaping LiShanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Hai-ke Rd, Shanghai 201203, China.
Feng LiHampton University School of Pharmacy, Kittrell Hall RM216, Hampton, VA 23668, USA.
Yongzhuo HuangShanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Hai-ke Rd, Shanghai 201203, China. Electronic address: yzhuang@simm.ac.cn.
Shanghai Institute of Materia Medica · CNChinese Academy of Sciences · CNGuangzhou University of Chinese Medicine · CNHampton University · USUniversity of Chinese Academy of Sciences · CN

Funding

Polymer-drug Conjugate Micelles for Treating Resistant Prostate CancersSC3GM109332 · NIGMS · HAMPTON UNIVERSITY · PI LI, FENG · 2014 to 2016
$333k
NIGMS NIH HHS SC3 GM109332
6 · The paper itself

Abstract

Poor tumor-targeted and cytoplasmic delivery is a bottleneck for protein toxin-based cancer therapy. Ideally, a protein toxin drug should remain stealthy in circulation for prolonged half-life and reduced side toxicity, but turn activated at tumor. PEGylation is a solution to achieve the first goal, but creates a hurdle for the second because PEG rejects interaction between the drugs and tumor cells therein. Such PEG dilemma is an unsolved problem in protein delivery. Herein proposed is a concept of turning PEG dilemma into prodrug-like feature. A site-selectively PEGylated, gelatinase-triggered cell-penetrating trichosanthin protein delivery system is developed with three specific aims. The first is to develop an intein-based ligation method for achieving site-specific modification of protein toxins. The second is to develop a prodrug feature that renders protein toxins remaining stealthy in blood for reduced side toxicity and improved EPR effect. The third is to develop a gelatinase activatable cell-penetration strategy for enhanced tumor targeting and cytoplasmic delivery. Of note, site-specific modification is a big challenge in protein drug research, especially for such a complicated, multifunctional protein delivery system. We successfully develop a protocol for constructing a macromolecular prodrug system with intein-mediated ligation synthesis. With an on-column process of purification and intein-mediated cleavage, the site-specific PEGylation then can be readily achieved by conjugation with the activated C-terminus, thus constructing a PEG-capped, cell-penetrating trichosanthin system with a gelatinase-cleavable linker that enables tumor-specific activation of cytoplasmic delivery. It provides a promising method to address the PEG dilemma for enhanced protein drug delivery, and importantly, a facile protocol for site-specific modification of such a class of protein drugs for improving their druggability and industrial translation.

Indexed as

InteinsAnimalsAntineoplastic Agents, PhytogenicCell Line, TumorDrug Delivery SystemsGelatinasesMiceNeoplasms, ExperimentalPolyethylene GlycolsProdrugsTreatment OutcomeTrichosanthinAntineoplastic Agents, PhytogenicGelatinasesPolyethylene GlycolsProdrugsTrichosanthinCell-penetrating peptideGelatinaseIntein-mediated protein ligation (IPL)Protein toxinSite-specific PEGylationTrichosanthin

Identifiers

PMID27914267
PMCPMC5527826
OpenAlexW2557030783

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.